Movement Alert｜Cigna Group Rises 4.8% in Regular Trading, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees

Market Focus06-05

On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of GLP-1 weight loss medications under its employee health plan effective July 1.

Cigna stated it will stop reimbursing GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for its workforce. The market interpreted this as a positive cost control signal. The company cited increased drug supply and emerging alternatives as the rationale, while clarifying that Type 2 diabetes prescriptions remain unaffected. With approximately 67,700 employees as of year-end, 88% of whom are based in the United States, the discontinuation is expected to meaningfully reduce employee medical plan expenditures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115779811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 00:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115779811","market":"us","top_or_hot":-1,"title":"Movement Alert｜Cigna Group Rises 4.8% in Regular Trading, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees","media":"Market Focus","content":"<p><p>On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of GLP-1 weight loss medications under its employee health plan effective July 1.</p><p>Cigna stated it will stop reimbursing GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for its workforce. The market interpreted this as a positive cost control signal. The company cited increased drug supply and emerging alternatives as the rationale, while clarifying that Type 2 diabetes prescriptions remain unaffected. With approximately 67,700 employees as of year-end, 88% of whom are based in the United States, the discontinuation is expected to meaningfully reduce employee medical plan expenditures.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Cigna Group Rises 4.8% in Regular Trading, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Cigna Group Rises 4.8% in Regular Trading, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 00:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of GLP-1 weight loss medications under its employee health plan effective July 1.</p><p>Cigna stated it will stop reimbursing GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for its workforce. The market interpreted this as a positive cost control signal. The company cited increased drug supply and emerging alternatives as the rationale, while clarifying that Type 2 diabetes prescriptions remain unaffected. With approximately 67,700 employees as of year-end, 88% of whom are based in the United States, the discontinuation is expected to meaningfully reduce employee medical plan expenditures.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CI","symbol_name":"信诺保险","start_time":0,"source_url":"","article_id":"1115779811","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115779811","pubTimestamp":1780589639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CI":"信诺保险"},"translate_title":"动静快讯|招商信诺集团常规交易涨4.8%宣布停止为员工报销GLP-1减肥药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1},"content_text":"On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of GLP-1 weight loss medications under its employee health plan effective July 1.Cigna stated it will stop reimbursing GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for its workforce. The market interpreted this as a positive cost control signal. The company cited increased drug supply and emerging alternatives as the rationale, while clarifying that Type 2 diabetes prescriptions remain unaffected. With approximately 67,700 employees as of year-end, 88% of whom are based in the United States, the discontinuation is expected to meaningfully reduce employee medical plan expenditures.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115779811","isCrawlerRequest":true}